Patients who reduced the frequency of GLP-1 dosing (from weekly to every other week) were able to maintain their weight loss and metabolic syndrome gains, as reported in this case series.
Findings suggest that while large increases in GLP1 levels may be necessary to induce weight loss, more modest elevations may be sufficient to maintain it.
Quote
Scott Isaacs
@scottisaacsmd
Reduced-frequency GLP-1 as a maintenance strategy: in this case series, patients who tapered from weekly semaglutide/tirzepatide to less frequent dosing maintained weight loss, body composition, and metabolic syndrome gains, supporting structured de-escalation to lower burden
